PMID- 32838502
OWN - NLM
STAT- MEDLINE
DCOM- 20200826
LR  - 20200826
IS  - 0578-1426 (Print)
IS  - 0578-1426 (Linking)
VI  - 59
IP  - 9
DP  - 2020 Sep 1
TI  - [The effects of continuous proton pump inhibitor therapy on small intestinal 
      bacterial overgrowth in elderly].
PG  - 706-710
LID - 10.3760/cma.j.cn112138-20191218-00823 [doi]
AB  - Objective: Long-term proton pump inhibitor(PPI) therapy may increase the risk of 
      small intestinal bacterial overgrowth(SIBO). Few studies on the effect of 
      on-demand and continuous PPI therapy are available in elderly. To investigate the 
      prevalence of SIBO and the effect of on-demand and continuous PPI therapy on SIBO 
      in elderly. Methods: A total of 200 elderly outpatients admitted to Department of 
      Gastroenterology at the Second Medical Center of PLA General Hospital were 
      enrolled and divided into 3 groups: continuous PPI group, on-demand PPI group and 
      control group. SIBO was diagnosed according to methane and hydrogen lactulose 
      breath test (LBT).The prevalence of SIBO in the 3 groups was analyzed. Results: 
      The prevalence of SIBO was 71.5% in 200 elderly. PPI therapy and diabetes 
      mellitus (DM) were independent risk factors for SIBO. The prevalence of SIBO was 
      77.1% (108/140) in elderly who underwent long-term PPI therapy and 58.3% (35/60) 
      in those without PPI therapy (P<0.01).The prevalence of SIBO was significantly 
      higher in continuous PPI therapy group than that in on-demand PPI group and 
      control group(88.6% vs. 65.7% and 58.3%, all P<0.01).However, no significant 
      difference was found in the prevalence of SIBO between on-demand PPI group and 
      control group (P>0.05). In elderly who underwent long-term PPI therapy, the 
      prevalence of SIBO increased significantly if administration time was longer than 
      61 months. Conclusions: SIBO usually occurs in elderly patients who receive 
      continuous PPI rather than on-demand use. If elderly require long-term PPI 
      therapy, on demand administration is suggested as long as primary diseases are 
      properly treated.
FAU - Zhang, R
AU  - Zhang R
AD  - Department of Gastroenterology, the Second Medical Center, Chinese PLA General 
      Hospital, National Clinical Research Center for Geriatric Diseases, Beijing 
      100853, China.
FAU - Li, Y
AU  - Li Y
AD  - Department of Gastroenterology, the Second Medical Center, Chinese PLA General 
      Hospital, National Clinical Research Center for Geriatric Diseases, Beijing 
      100853, China.
FAU - Ma, J X
AU  - Ma JX
AD  - Department of Gastroenterology, the Second Medical Center, Chinese PLA General 
      Hospital, National Clinical Research Center for Geriatric Diseases, Beijing 
      100853, China.
FAU - Tang, S
AU  - Tang S
AD  - Department of Gastroenterology, the Second Medical Center, Chinese PLA General 
      Hospital, National Clinical Research Center for Geriatric Diseases, Beijing 
      100853, China.
FAU - Li, C M
AU  - Li CM
AD  - Department of Gastroenterology, the Second Medical Center, Chinese PLA General 
      Hospital, National Clinical Research Center for Geriatric Diseases, Beijing 
      100853, China.
FAU - Wan, J
AU  - Wan J
AD  - Department of Gastroenterology, the Second Medical Center, Chinese PLA General 
      Hospital, National Clinical Research Center for Geriatric Diseases, Beijing 
      100853, China.
LA  - chi
GR  - 17BJZ46/Chinese PLA Special Research Projects of Health Care/
GR  - 2017FC-TSYS-2020/Clinical Research Fostering Fund of Chinese PLA General 
      Hospital/
PT  - Journal Article
PL  - China
TA  - Zhonghua Nei Ke Za Zhi
JT  - Zhonghua nei ke za zhi
JID - 16210490R
RN  - 0 (Proton Pump Inhibitors)
RN  - 4618-18-2 (Lactulose)
SB  - IM
MH  - Aged
MH  - *Bacterial Infections/drug therapy
MH  - Breath Tests
MH  - Humans
MH  - Intestine, Small
MH  - Lactulose
MH  - Proton Pump Inhibitors/*therapeutic use
OTO - NOTNLM
OT  - Aged
OT  - Methane and hydrogen breath test
OT  - Proton pump inhibitors
OT  - Small intestinal bacterial overgrowth
EDAT- 2020/08/26 06:00
MHDA- 2020/08/28 06:00
CRDT- 2020/08/26 06:00
PHST- 2020/08/26 06:00 [entrez]
PHST- 2020/08/26 06:00 [pubmed]
PHST- 2020/08/28 06:00 [medline]
AID - 10.3760/cma.j.cn112138-20191218-00823 [doi]
PST - ppublish
SO  - Zhonghua Nei Ke Za Zhi. 2020 Sep 1;59(9):706-710. doi: 
      10.3760/cma.j.cn112138-20191218-00823.